PYTX 003
Alternative Names: PYTX-003Latest Information Update: 04 Nov 2022
Price :
$50 *
At a glance
- Originator Papyrus Therapeutics; Targovax
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Immunostimulants; Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Ovarian cancer
Most Recent Events
- 10 Oct 2022 Early research in Ovarian cancer in Norway (Parenteral), prior to October 2022 (Papyrus Therapeutics pipeline, October 2022)
- 10 Oct 2022 Early research in Ovarian cancer in USA (Parenteral), prior to October 2022 (Papyrus Therapeutics pipeline, October 2022)
- 10 Oct 2022 Papyrus Therapeutics plans a lead development candidate selection in the first half of 2023 (Papyrus Therapeutics pipeline, October 2022)